Tower Research Capital (TRC)’s Champions Oncology CSBR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-501
| Closed | -$4.35K | – | 5299 |
|
|
2025
Q1 | $4.35K | Sell |
501
-1,139
| -69% | -$11.5K | ﹤0.01% | 4270 |
|
|
2024
Q4 | $14.1K | Sell |
1,640
-913
| -36% | -$4.59K | ﹤0.01% | 3482 |
|
|
2024
Q3 | $12.4K | Buy |
+2,553
| New | +$12K | ﹤0.01% | 3591 |
|
|
2023
Q4 | – | Sell |
-21
| Closed | -$130 | – | 5954 |
|
|
2023
Q3 | $130 | Buy |
21
+15
| +250% | +$95 | ﹤0.01% | 5696 |
|
|
2023
Q2 | $38 | Sell |
6
-2,651
| -100% | -$13.7K | ﹤0.01% | 5886 |
|
|
2023
Q1 | $10K | Buy |
2,657
+698
| +36% | +$2.98K | ﹤0.01% | 4335 |
|
|
2022
Q4 | $9K | Buy |
1,959
+1,941
| +10,783% | +$12.7K | ﹤0.01% | 4181 |
|
|
2022
Q3 | $0 | Sell |
18
-15
| -45% | -$125 | ﹤0.01% | 6113 |
|
|
2022
Q2 | $0 | Buy |
+33
| New | +$252 | ﹤0.01% | 6128 |
|
|
2021
Q4 | – | Sell |
-117
| Closed | -$1K | – | 6189 |
|
|
2021
Q3 | $1K | Sell |
117
-558
| -83% | -$5.68K | ﹤0.01% | 5444 |
|
|
2021
Q2 | $7K | Sell |
675
-1,564
| -70% | -$15.9K | ﹤0.01% | 4547 |
|
|
2021
Q1 | $26K | Sell |
2,239
-641
| -22% | -$7.44K | ﹤0.01% | 3673 |
|
|
2020
Q4 | $31K | Sell |
2,880
-3,963
| -58% | -$40.9K | ﹤0.01% | 3535 |
|
|
2020
Q3 | $63K | Buy |
6,843
+1,554
| +29% | +$13.8K | ﹤0.01% | 3437 |
|
|
2020
Q2 | $50K | Buy |
5,289
+5,097
| +2,655% | +$43.4K | ﹤0.01% | 3042 |
|
|
2020
Q1 | $1K | Sell |
192
-1,665
| -90% | -$11.6K | ﹤0.01% | 2748 |
|
|
2019
Q4 | $15K | Sell |
1,857
-568
| -23% | -$3.51K | ﹤0.01% | 2094 |
|
|
2019
Q3 | $14K | Buy |
2,425
+912
| +60% | +$5.92K | ﹤0.01% | 2718 |
|
|
2019
Q2 | $12K | Buy |
1,513
+1,101
| +267% | +$9.66K | ﹤0.01% | 2449 |
|
|
2019
Q1 | $4K | Sell |
412
-632
| -61% | -$6.3K | ﹤0.01% | 3146 |
|
|
2018
Q4 | $8K | Buy |
+1,044
| New | +$12K | ﹤0.01% | 2612 |
|
|
2018
Q3 | – | Sell |
-1,799
| Closed | -$11K | – | 3826 |
|
|
2018
Q2 | $11K | Buy |
1,799
+46
| +3% | +$221 | ﹤0.01% | 2725 |
|
|
2018
Q1 | $6K | Sell |
1,753
-780
| -31% | -$2.91K | ﹤0.01% | 2647 |
|
|
2017
Q4 | $10K | Buy |
+2,533
| New | +$9.03K | ﹤0.01% | 2544 |
|
|
2016
Q4 | – | Sell |
-788
| Closed | -$1K | – | 3882 |
|
|
2016
Q3 | $1K | Buy |
788
+300
| +61% | +$558 | ﹤0.01% | 3273 |
|
|
2016
Q2 | $1K | Buy |
+488
| New | +$1.53K | ﹤0.01% | 4135 |
|
|
2016
Q1 | – | Sell |
-200
| Closed | -$1K | – | 4225 |
|
|
2015
Q4 | $1K | Buy |
200
+153
| +326% | +$658 | ﹤0.01% | 4042 |
|
|
2015
Q3 | $0 | Buy |
+47
| New | +$307 | ﹤0.01% | 4103 |
|
Other funds holding CSBR
BMC
NMC
TAM
Tower Research Capital (TRC)'s CSBR Position: Q2 2025 in Review
Tower Research Capital (TRC) sold out of Champions Oncology (CSBR) in Q2 2025, closing a stake of 501 shares — an estimated $4.35K sold.
Tower Research Capital (TRC) first reported a position in CSBR in Q3 2015 and held it in 28 quarters. The position peaked at $63K in Q3 2020. 30 funds tracked by Wall St. Rank hold CSBR as of Q2 2025.
- Tower Research Capital (TRC) reported no remaining Champions Oncology position as of Q2 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 501 Champions Oncology shares in Q2 2025, an estimated $4.35K.
- Tower Research Capital (TRC) first reported a position in Champions Oncology in Q3 2015 and held it in 28 quarters.
- Tower Research Capital (TRC)'s Champions Oncology position peaked at $63K in Q3 2020.
- 30 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.